Litcius/Paper detail

Hepatic Arterial Infusion Chemotherapy as a Timing Strategy for Conversion Surgery to Treat Hepatocellular Carcinoma: A Single-Center Real-World Study

Jiongliang Wang, Zhikai Zheng, Tianqing Wu, Wenxuan Li, Juncheng Wang, Yangxun Pan, Wei Peng, Dandan Hu, Jiajie Hou, Li Xu, Yaojun Zhang, Minshan Chen, Rongxin Zhang, Zhongguo Zhou

2022Journal of Hepatocellular Carcinoma20 citationsDOIOpen Access PDF

Abstract

Objective: To evaluate whether surgery-related complications are increased after hepatic arterial infusion chemotherapy (HAIC) using oxaliplatin plus fluorouracil/leucovorin for conversion compared with primary hepatocellular carcinoma (HCC) resection and the optimal timing of conversion surgery (CS). Background: HAIC has been widely used for advanced HCC, especially initially unresectable HCC, to facilitate conversion to curative-intent resection in approximately 23.8% of cases. However, the optimal timing of surgery to reduce surgical complications must be clarified. Methods: Data from 320 HCC patients, including 107 initially unresectable patients in the HAIC-Surgery group and 213 patients in the Surgery group, were retrospectively collected and analyzed. Survival outcomes and the incidence of surgery-related complications were compared. Results: There was no significant difference in recurrence-free survival (RFS) between the HAIC-Surgery group and the Surgery group (HR: 1.140, 95% CI: 0.8027– 1.618, p =0.444). The HAIC-Surgery group had a higher incidence of surgery-related complications than the Surgery group [biliary leakage (10.3% vs 4.2%, p =0.035), abdominal bleeding (10.3% vs 3.8%, p =0.020), pleural effusion (56.1% vs 23.0%, p < 0.0001) and ascites effusion (17.8% vs 5.2%, p < 0.0001)]. In the HAIC-Surgery group, postoperative liver function decreased and abdominal bleeding increased with more preoperative HAIC cycles (Spearman=0.229, p =0.042, Spearman=0.198, p =0.041, respectively). The pathological complete remission (pCR) rate after 3– 5 HAIC cycles was significantly higher than that after 1– 2 cycles (29.4% vs 13.2%, p =0.043). Conclusion: The prognosis of advanced HCC after conversion surgery is comparable to that after direct surgery. Rather than increasing pCR, more HAIC cycles can exacerbate liver dysfunction and surgery-related complications. Keywords: hepatocellular carcinoma, conversion therapy, hepatic artery chemotherapy infusion

Topics & Concepts

MedicineSurgeryHepatocellular carcinomaPleural effusionAscitesOxaliplatinSingle CenterIncidence (geometry)Abdominal surgeryGastroenterologyInternal medicineColorectal cancerCancerPhysicsOpticsHepatocellular Carcinoma Treatment and PrognosisOrgan Transplantation Techniques and OutcomesCholangiocarcinoma and Gallbladder Cancer Studies